Table 1 Clinical and biological characteristics of the study population at baseline
Characteristics | N = 107 |
|---|---|
Age (years) | 56.6 ± 13.5 |
Disease duration (years) | 9.9 ± 8.1 |
Gender (M/F) | 29 (27.1)/78 (72.9) |
DAS28-ESR | 4.93 ± 1.3 |
Extra articular manifestations | |
Nodules | 18 (16.8) |
Sicca syndrome | 15 (14) |
Vasculitis | 2 (1.8) |
X-ray erosions | |
Presence | 68 (66.6) |
Absence | 34 (33.3) |
ND | 5 (4.6) |
csDMARDs | 77 (71.9) |
MTX | 66 (61.7) |
LEF | 10 (9.3) |
SLZ | 0 |
HCQ | 1 (0.9) |
Glucocorticoids | 74 (69.2) |
Dosage (mg/day) | 6.8 |
Previous bDMARDs | 69 (64.5) |
TNFi | 67 (62.6) |
Rituximab | 5 (4.6) |
Abatacept | 13 (12.1) |
Anakinra | 1 (0.9) |
Rheumatoid factors | 81 (75.7) |
Anti-CCP antibodies | 82 (76.6) |
CV risk factor: | |
Hypertension | 40 (37.3) |
Diabetes# | 7 (6.5) |
Dyslipidaemia## | 19 (17.7) |
Smoking | |
Never | 65 (60.1) |
Previous | 20 (18.7) |
Current | 22 (20.5) |